After being fired, I became the light of medicine

Chapter 238 I’m going to learn Chinese. I’m afraid I won’t be able to read Chinese journals!
After the meal, Zhang Yang was a little confused.

Of course, he didn't know that he and Wei Tian would be recognized whenever they went to a restaurant, and that people would secretly pay for him.

When he returned to the company, he came to his senses and gradually realized the truth of the matter. It is possible that a patient who recognized him secretly paid the bill for him.

Thinking of this, his heart warmed up, and suddenly he felt an indescribable feeling.

The cost of a meal is nothing to him, but... the feeling of being recognized is really good!
After expressing his feelings, Zhang Yang quietly hid this warmth deep in his heart and immediately began to focus more on the clinical trials of "Ibelumab".
All he can do is work hard to develop drugs that can cure diseases and save lives.

……

While clinical trials of Ibetuzumab were being carried out in an orderly manner in China, the news that Tsingshan Pharmaceutical had developed Ibetuzumab, a drug for treating leukemia, finally appeared on foreign social media through the Internet.

《Shocked! China's well-known pharmaceutical company Qingshan Pharmaceutical has developed the latest drug for the treatment of leukemia! 》

《The latest news: The first drug to treat acute myeloid leukemia in human history has started clinical trials in China. Leukemia will usher in a historic breakthrough! 》

《There is hope! The latest progress in the development of leukemia drugs has been reported from the ancient Eastern country—chemical name: Ibetumumab!》

"Popular Science! Why is Qingshan Pharmaceutical's 'Ibeumab' expected to become a miracle drug for the treatment of leukemia! "

Not only foreign social media, but also the professional medical journal "The Lancet" published news about "Ibetuzumab" for the first time.

Royal London Hospital, UK.

The Royal London Hospital is the best hospital in the UK, and its hematology department is its advantage department. It is one of the top departments in Europe and even in the world.

Dr. Richard is the top professor in the department. Besides him, there are several other equally prestigious professors in the department.

In the department conference room, after the department meeting, the professor team led by Dr. Richard began to discuss the news about Tsingshan Pharmaceutical's "Ibeumab".

"Dr. Richard, yesterday I saw several news reports on Twitter about the Chinese pharmaceutical company Qingshan Pharmaceutical developing a targeted drug called 'Ibeumab'..."

"You may not know that this is a drug used to treat 'acute myeloid leukemia'... I originally thought that the media was just making up stories, but I didn't expect that this morning, the latest issue of The Lancet actually reported this news!"

"It's unbelievable. Have you noticed the news?"

Dr. Richard nodded as he sorted out the information on the conference table:

"I noticed it, and... I noticed the news when the Twitter news first came out yesterday."

"I even went to Qingshan Pharmaceutical's official website to check! Yes, there is indeed news about this drug, and they have already started clinical trials in China!"

"Oh?! Do you think their 'Ibetumumab' can really achieve an 80% therapeutic effect on 'acute myeloid leukemia' as they revealed?! Why do I feel that it is a bit exaggerated and it is fake news?!"

"False news?"

Dr. Richard paused for a moment, then stopped what he was doing and shook his head:

"Motta, if the news was released by other Chinese biopharmaceutical companies, I would definitely not believe the data they revealed. At least I would be skeptical!"

"but!"

"This is Qingshan Pharmaceutical!"

Motta is also a doctor, and an Indian medical doctor. He was slightly stunned when he heard this.

Dr. Richard saw this and couldn't help but smile. His eyes flashed with admiration and he continued:
"In recent years, they have developed a number of top-notch drugs in the field of biopharmaceuticals. The very familiar 'ITG human myelopoietin' and the epoch-making 'Kidney Toxin Clearing Dialysis Needle' are all from their hands."

“Moreover, the effects of these top drugs that eventually come to market are almost the same as the treatment effects they were designed to achieve when they were first put into clinical trials!”

"So, we can be sure that they must have conducted sufficient animal experiments in the laboratory, and only after sufficient verification can the final results of the clinical data be announced. The difference will not be too outrageous!"

"So, it can be seen that Qingshan Pharmaceutical will never do something without a purpose. It must be fully confident."

As he finished speaking, Indian-American Dr. Motta quickly recalled the clinical trial data of several drugs recently developed by Qingshan Pharmaceutical.

After a moment, he shook his head and said:
"Dr. Richard, I don't deny that the facts seem to be similar to what you said."

"However, I still think it is unlikely that a Chinese pharmaceutical company could develop such a targeted drug for 'acute leukemia' that can achieve a therapeutic effect of about 80%!"

"Not too possible?"

"Ok!"

As he spoke, Indian doctor Mota nodded and continued:
"You know, 'acute myeloid leukemia' is strictly speaking a very serious blood cancer!"

"Cancer cells are naturally difficult to overcome, with strong escape potential and high degree of mutation. Therefore, it has always been difficult for targeted drugs for various cancers to achieve a long-term treatment effect of more than 80%, let alone long-term control!"

"We in the West have records of studying leukemia since 1811, and modern medicine officially started developing leukemia drugs in 1910."

"For more than a hundred years, our Western pharmaceutical companies have not developed targeted drugs that can treat and control 'acute myeloid leukemia'. How could it be possible for backward Chinese pharmaceutical companies to suddenly make such a major breakthrough in this regard!"

"You know, Chinese pharmaceutical companies are obviously lagging behind us in the West in terms of both talent and knowledge reserves, so..."

"I strongly doubt that the effect of their 'ibumaxin' this time will not be as good as they say!"

“Could this be a fraud?”

Dr. Richard glanced at Motta in surprise as he retorted.

He has always recognized Mota's academic level, but he did not expect that Mota would have such outrageous ideas about Qingshan Pharmaceutical.

Is Tsingshan Pharmaceutical committing fraud?

What's the motive?
Shrugging his shoulders, he said noncommittally:
"Motta, have you forgotten that they developed a drug that can cure aplastic anemia seven years ago?!"

"Moreover, you just said: 'Chinese pharmaceutical companies are obviously lagging behind our Western pharmaceutical companies in terms of talent reserves and knowledge reserves'...

Do you know how much R&D funds Qingshan Pharmaceutical has invested in recent years and how many R&D personnel it has recruited to develop new drugs? "

"Also, I feel like you don't seem to know your next-door neighbor Hua Xia very well.
I have been to Huaxia many times, and the doctors and researchers there are very smart, humble and good at learning. "

"Especially the top doctors and top drug researchers almost all have studied abroad." "So, I don't think there is any big gap between the researchers there and our Western researchers!"

"To make an inappropriate analogy, we in the Western world used to think that their chips were inferior to ours; without our patent authorization, they would never be able to solve the chip problem!"

"But now... they are already able to develop top-level chip manufacturing processes, and ASML has no choice but to restart its lithography machine sales plan and beg them to sell it!"

"and……"

“Who would have thought that they would even suddenly develop a sixth-generation aircraft?”

As he said this, Dr. Richard shrugged and then looked at Indian Dr. Motta.

"I heard that when the news came out, the main roads near the White House were jammed in the early morning...

I guess those people in the White House thought it was fake after hearing it, just like you, but the result is... whether it is the Chinese government or Qingshan Pharmaceutical, they seem to have never done such a thing, nor would they bother to do it!"

Dr. Motta suddenly looked a little angry. He didn't expect that his reasonable suspicion would lead to such an impolite response from Dr. Richard.

Excessive!

At this time, another white hematologist took over the conversation and said:

"Dr. Richard, if it's true as you said, then Qingshan Pharmaceutical's R&D capabilities are too terrifying!"

"I remember a few years ago, when AkaRx first developed 'Avatrombopag', which is specifically designed to increase platelets, our industry was cheering that blood patients finally had the latest generation of first-line treatment drugs to increase blood counts."

"But just two years later, Qingshan Pharmaceutical not only developed 'Qingshan Ava' which also has the effect of increasing platelets, but also developed 'ITG human myelopoietin' which can completely cure aplastic anemia."

"It's only been five or six years now. Is it possible that even the most difficult blood disease, 'Acute Myeloid Leukemia', can be controlled?"

"Of course, we should be happy about the great progress in medicine, but..."

As he was speaking, the white doctor's face suddenly fell, and he said dejectedly:
"You haven't forgotten, right? In the first two years after 'ITG Human Myelopoietin' was launched in China, countless patients, even members of the royal family, went to China for treatment. We didn't even admit any patients with 'Aplastic Anemia' for a whole year."

"After Sloan-SmithKline introduced 'ITG human myelopoietin' in the past two or three years, we were finally able to develop a treatment plan for 'plastic anemia'. But if Qingshan Pharmaceutical really develops a targeted drug with good therapeutic effects on 'acute leukemia', we are afraid that we will lose a large number of patients in a short period of time."

"Doctor, why are they here again!"

Hearing this, Dr. Richard couldn't help but smile bitterly.

indeed,

Six or seven years ago, when Tsingshan Pharmaceutical had not yet developed "ITG human myelopoietin", all hospitals in the world had no particularly effective treatment options for "aplastic anemia".

The Royal London Hospital has attracted many high-ranking officials, nobles and top wealthy people from all over the world to come for treatment thanks to its long-standing reputation for hematology and some unique treatment plans.

But what happens after “ITG Human Myelopoietin” is launched on the market?
Who the hell is coming?!

They all went to Huaxia Hospital. Union Hospital, Ruijin Hospital, Fudan University, these top hospitals in China became the first choice for the rich.

If this "Ibetumumab" is really as effective as Qingshan Pharmaceutical advertises, he is almost certain that the number of patients visiting the department will be greatly affected for a long time.

This is just part of it!

More importantly – academic status!
I remember that in the first two years after "ITG human myelopoietin" was developed and launched on the market, almost all academic seminars related to blood diseases and blood disease columns in all top medical journals in the world were dominated by Chinese hematology professors.

Published a large number of papers on the treatment of aplastic anemia!
These papers were read and studied by general hematologists around the world, providing countless doctors around the world with valuable experience in using "ITG human myeloid foetus" for treatment, and eventually gradually formed a globally recognized standard treatment plan for the disorder!
It is no exaggeration to say that the current international standard plan for the treatment of aplastic anemia was developed by Chinese professors!
This makes a top doctor like Richard feel a little uncomfortable.

You know, before this, the treatment plans they summarized and published were the gold standard and were highly sought after by their peers.

But there is no way, this is how the academic world is, who lets Huaxia Hospital and Huaxia professors always have first-hand treatment opportunities? !

Thinking of this, he suddenly panicked and hurriedly picked up the materials sorted out on the conference table:

"David, you reminded me that I have to deal with the patients I have as soon as possible. I have to go to China as soon as possible!"

David is the white doctor standing next to him.

"You, you are going to China again?"

"Ah."

Dr. Richard nodded, and suddenly felt quite emotional:
"There is a Chinese saying that goes, 'Thirty years in the east, thirty years in the west.' Previously, Chinese doctors tried every means to come to our hospital to learn the most advanced treatment plans."

"Now, it's our turn. If we want to learn about the most advanced treatment options in the world, we must go to China to study."

"I can't go two years without publishing a paper on leukemia again, can I? I have to see if I can contact a hospital to study closely!"

"..."

David was silent, and even the Indian doctor Motta, who had been unhappy, was stunned.

At this moment, Dr. Richard stood up:
"Oh, by the way, I'm going to start learning Chinese seriously!"

“I’m afraid that when their latest papers are published in Chinese, I won’t be able to understand them.”

David was stunned, thought for a moment and nodded:

"Doctor, what you said makes sense. I should also learn some Chinese."

"When you go to China this time, I want to go with you. To be honest, I don't know much about this distant Eastern country."

After saying this, his eyes fell on the Indian doctor Mota standing beside him:
"Dr. Motta, would you like to go to China with me?"

Mota's face turned pale:

"No, I'm not going!"

(End of this chapter)